











Manuscript version: Published Version 
The version presented in WRAP is the published version (Version of Record). 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/148835                            
 
How to cite: 
The repository item page linked to above, will contain details on accessing citation guidance 
from the publisher. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  
 
Copyright © and all moral rights to the version of the paper presented here belong to the 
individual author(s) and/or other copyright owners. To the extent reasonable and 
practicable the material made available in WRAP has been checked for eligibility before 
being made available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge. Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 





Embracing Change: Learnings From
Implementing Multidimensional Digital Remote
Monitoring in Oncology Patients at a District
General Hospital During the COVID-19 Pandemic
Sandra Komarzynski, Dipl. Ing., MSc1; Nicholas I. Wreglesworth, MBBS2,3; Dawn Griffiths, NP2; Leandro Pecchia, PhD4;
Christian P. Subbe, MD3,5; Stephen F. Hughes, BSc (Hons), MPhil, PhD, CSci6; Elin H. Davies, RN, BSc, MSc, PhD1; and
Pasquale F. Innominato, MD, PhD2,7,8
A combination of newer treatments, better diagnostics,
and earlier interventions means more people live with
and are treated for cancer than ever before.1 Although
in terms of scientific breakthrough, this is clearly
positive, clinical pathways and the systems in place to
deliver these treatments have not much changed for
20 years. Embracing technology must be part of the
solution to improve efficiency, to safely deliver treat-
ments and improve patient’s experience with oncology
care.2,3
The COVID-19 pandemic has forced this issue to the
forefront.4,5 Increasing staff sickness and clinical as-
sessments largely over the phone, using innovative
technology, particularly in the outpatient setting,
should now be a must.
Our oncology unit consists of a 20-bedded inpatient
ward, 20-chair chemotherapy delivering unit, outpatient
department, and acute oncology–specific receiving
unit. It is associated with a main hospital site and
benefits from subspecialty advice with any level II or III
care required. Our vision is for each oncology patient
undergoing anticancer treatment to have vital signs and
circadian metrics monitored continuously over the
entirety of their oncology care. This can be achieved
through a multidisciplinary integrative approach in-
volving clinicians of different specialties, nurses,
healthcare professionals, and biomedical engineers.
There is rapidly growing evidence demonstrating the
predictive value of large patient-generated data in an-
ticipating deterioration, optimizing care, and guiding
treatment changes.6-10 Although the bioinformatics pre-
dictive methodology rapidly develops, building systems
on existing older technology is becoming a major bot-
tleneck to success. Developing environments that allow
validated easy-to-use devices and applications to com-
plement busy service departments without becoming
additional time burden is key to a viable useful solution.
We plan to develop a three-phase process to attain our
ambitions. We present the first phase here. Forty-eight
randomly selected patients with cancer were given a
wearable device (Garmin Vı́vosmart 411) connected to
a bespoke smartphone application “Nitrogen by
Aparito” (iOS and Android compatible), designed by
the MedTech company Aparito12 and funded by NHSX
Techforce 19 and SMART Cymru as part of their
COVID response fund for a specific duration of
2 weeks.13 Nitrogen is a version of the Atom5 platform
(Fig 1). Vı́vosmart 4 is an off-the-shelf lifestyle watch
that records heart rate, accelerometer, ambient light,
and pulse blood oxygen saturation (SpO2). The per-
formance of this device has been compared with
similar consumer activity trackers in studies assessing
outcomes related to physical activity, sleep, and heart
rate, with overall satisfactory results.14-16 Nonetheless,
Vı́vosmart 4 used here is one of the few armbands
equipped with a pulse oximeter, which we reputed
chiefly relevant with regard to COVID-19 symptom-
atology and remote surveillance.17,18
Twenty-six participants were male and 22 female.
Each of them completed informed consent. Patients’
average age was 65 years (range, 31-80 years). As a
group, they reflect a real-life cohort expected to attend
an oncology outpatient department.
Phase I coincided with the COVID-19 peak in the
United Kingdom (April 2020). As this was a proof-of-
concept project attempting to outline the feasibility of
rapidly implementing tailored patient monitoring, we
selected COVID-19–based patient-reported symptoms
highlighted by Public Health governing bodies at that
time.19 Specifically, Nitrogen presented once daily yes/
no questions on new/worsening cough, breathing
difficulties, fever/temperature, unusual/worse than
usual fatigue, and general well-being. The patients
could also tick the symptoms they were experiencing
from a pre-established list including body aches/chills,
nausea, vomiting, appetite/smell/taste loss, and ab-
dominal pain. Objective measurements of spot-check
SpO2 and continuous heart rate and physical activity
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identified potential COVID-like symptoms were assessed
daily for subjective deterioration through the mobile ap-
plication with an alert and notification sent to patients to
complete. Vital sign measurements from the device and
patient-reported symptoms were collated and displayed
within a central easy-to-use web-based dashboard for re-
sponsible clinicians and healthcare professionals to assess.
Forty (83%) of the patients who were consented ultimately
recorded data, demonstrating that the application was an
accessible technology solution for the majority of patients.
In general, the patients demonstrated a high engagement
with completing the questionnaire, recording symptoms for
a median of 9 days. The monitoring duration varied from 1
to 14 days depending on the patients’ consent date during
the project timelines (a fortnight). Overall, there was a
positive commitment to the process, and this was con-
firmed by an impressive median adherence rate of 89%,
comparing favorably with other similar COVID-19–specific
or general cancer digital solutions.20-22
Physiological metrics were monitored by the wristband
worn day and night for the continuous measurement of
heart rate, the motion intensity patterns, and the nightly
assessment of SpO2. Additionally, patient-triggered snap-
shot measurements of SpO2 were possible during daytime.
When evaluating our target population before amendments
for phase II of our plans, one of themost notable reasons for
not engaging was user-operator related. Of the twelve
patients who had minimal use of the application, the
majority struggled to activate the Bluetooth connection on
their mobile phone to allow linking the application to their
wearable device or mistakenly used the Garmin Connect
App, which prevented clinicians from receiving the data on
the Nitrogen app. As a result, data were collated from the
wearable devices of 34 patients (71%). Patients showed
slightly less engagement with the wearable device’s use
than with the symptoms questionnaire, as reflected by the
median adherence to device’s use of 79%. The most
commonly reported difficulty was related to the device
screen being too small for patients to read and navigate the
display. Another key engagement issue was the expressed
wish by the majority of patients to being able to track their
own data directly on the application. Patients encouraged
the development team to adapt and develop version II.
Thirty-one patients were still using the technology at week 5
and 21 at week 13 without any prompting, reminder, or
further intervention from the clinical team.
Overall, the response to the remote monitoring technology
was greatly positive. A short feedback survey conducted in
a self-selecting subgroup of 22 patients revealed that the
patients were overall satisfied with both the application and
wearable device. On a Likert scale from 0 (not at all) to 10
(very much), the patients rated the easiness of the appli-
cation’s use with an average score of 8.3, and of 6.9 to the
wearable device’s utilization. Furthermore, the patients felt
comfortable with using the application on their phone to
communicate their symptoms (average: 9.3) and with
carrying a wearable device to share their physiological
metrics with their doctors (average: 8.7). The feedback
regarding the device screen, the onboarding process, and
the desire to self-monitoring being included have been

































FIG 1. Technical architecture of the Atom5 platform used in this deployment. The data flow and storage is illustrated in the cloud, with encryption at
transfer and rest depicted. Auth, authorization; TLS, Transport Layer Security.
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Developing bespoke monitoring systems for individual
patients undergoing systemic anticancer therapy will be-
come standard of care eventually. Our first phase imple-
mented rapidly during the viral crisis has offered us
valuable insight into the practicalities of implementing a
system as we move to more comprehensive deployments.
High-quality governance is an essential cornerstone of this
approach if it is to be accepted long term. Although such
big data are likely to provide valuable insights into patients’
clinical outcomes, their privacy must not be sacrificed in a
bid to achieve this, and as such, the protection of this
personal patient-generated data is vital. In our phase I
deployment, Information Governance approval and pa-
tient onboarding were all achieved within 2 weeks; this
process could well have taken upward of 2 months before
the COVID-19 pandemic. The facilitation of speedier
decision making and implementation are hugely topical
aspects that have allowed significant progress in our
monitoring plans, and we hope that they remain in health
care after COVID-19.
Some of the major limitations and therefore learning points
of our first phase were based on the assumption of what is
patient IT literacy. We assumed that patients knew how to
connect to Wi-Fi, navigate an app store, and use Bluetooth
connectivity. Although these issues were by no means the
norm, they did highlight a potential disenfranchised group
whom we need to support and cater for.
Finding the balance of using key clinicians time and col-
lecting meaningfully actionable data means that our future
infrastructure budgeting will change. Redesigning of
workflow will allow nonclinical staff with dedicated time to
onboard initially less capable patients and upskill those with
an interest while enabling trained and experienced
healthcare professionals to focus on analyzing and triaging
trends highlighted by the data.
In conjunction with this, finding a balance between a
validated minimally invasive device that is easy to use for a
patient with poorer eyesight and less fine motor dexterity
was probably our biggest ongoing concern.
Since being able to visualize their own data was of major
interest to patients, we believe that the addition of this feature
to future rollouts will be likely to increase participation’s
length and patient’s engagement. Notwithstanding, it is
important to strike the balance between empowering and not
overwhelming patients with information. Not to be over-
loaded with questions was another highlighted aspect by the
participants. These are not novel insights into patient’s habits
and requirements for digital monitoring studies.23,24
Monitoring devices can be either lifestyle and/or consumer
or medically certified. Inherently, health professionals veer
to medically registered devices because of absolute need
for accurate, reliable, and repeatable data to justify clinical
decisions. Patients, however, are much more likely to
provide longer periods of data monitoring with a lifestyle
and/or consumer device given its focus on being easy-to-
use, esthetically pleasant, and practical.25,26
There are several examples of validated, or undergoing
clinical trials, novel medical devices. These devices are
aimed explicitly to be clinically accurate but often designed
for a short-term assessment period and as such come with
more taxing fitting conditions.
Manufacturers of lifestyle devices, particularly in the
COVID-19 pandemic era, are moving into an economic
space capitalizing on the general population’s desire for
medical monitoring. They are teaming with large research
institutions; examples include the Scripps Research
Translational Institute with FitBit’s DETECT health study27
and Stanford Healthcare Innovation lab who are working
with multiple lifestyle devices including Fitbit, Garmin,
Samsung, Apple, and Oura.28,29
In our initial case series, we noticed several staff members
and patients in good health condition recording low satu-
rations that were up to 10% lower compared with readings
found using in-hospital medical grade devices. This
highlighted the absolute need to carefully deploy chosen
devices in validating study as a prerequisite before any use
in a decision-making capacity.
Despite the growing interest in mobile sensing in
oncology3 and with COVID-19,18,30 and the multiple
smartphone apps and digital platforms for symptom
monitoring in patients with cancer,31-35 most COVID-
19–specific monitoring in patients with cancer worldwide
has been using mainly patient-reported symptoms and not
passive biosensing.36-40
With this blurring between the more traditionally designed
medical devices and the rapidly evolving lifestyle
trackers, justifiable scientific validation becomes critical.
One important feature from our initial study suggested
that patients have a wide reference range of what they
consider easy to use. We believe that a combination of
offered devices will lead to the most comprehensive,
individualized, and long-term engagement—likely in the
form of watches and/or armbands,41 rings,42 transdermal
patches,43 or even integrated solutions using multiple
dedicated sensors.44,45
Our series informally gather the key staff members’ opinion
of efficiency. Although trial processes are inherently inef-
ficient cited by the initial onboarding of patients, there was a
general buy-in that optimizing this technique is a pro-
gressive step and dedicated nursing support has been
funded to investigate streamlining a protocol.
As our series moves through phase II (recruiting targeted
acutely unwell patients to monitor their progress as inpa-
tient and outpatient) and phase III (general new patient
recruitment), assessment, reliability, and quality checks of
the monitoring device with medical grade specifications will
be critical to success. Phase II will additionally look to
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compare the vital signs measured on standard medically
accepted and certified observation machines based in the
unit used for the development of the NEWS score46 with our
device(s). Improved versions of the application will evolve
over the phases as we optimize patient-specific queries and
incorporate cancer-specific pathways and other aspects
that support our multidisciplinary team (specialist cancer
nurses, physiotherapists, nutritionists, and clinical psy-
chologists) to provide a holistic, tailored, and integrative
support for our patients with cancer.
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